CAL-1-transduced hematopoietic stem cell gene therapy (Calimmune)

N/A

Report date: 2023/01/12 15:52:02

Base Information

Drug NameCAL-1-transduced hematopoietic stem cell gene therapy (Calimmune)
Drug Alias NameLVsh5C46Cal 1 therapyCal 1-modified HSPCLVsh5C46-transduced-HSPCCal-1
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionC-C chemokine receptor type 5 modulators
TargetsC-C chemokine receptor type 5
Therapy Area/IndicationsNeoplasm MetastasisBreast NeoplasmsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCalimmune Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChugai Pharma USA, IncCalimmune Inc
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisBreast NeoplasmsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A